Investor Relations
Vidac Pharma Holdings PLC — listed on Xetra, Tradegate, Hamburg, Stuttgart and Düsseldorf
Stock Information
Data provided by TradingView. Exchange: XETRA | Ticker: T9G
Key Share Information
- Symbol
- T9G
- ISIN
- GB00BM9XQ619
- WKN
- A3DTUQ
- LEI
- 875500BCH1T6XX5EUG13
- Exchanges
- Hamburg · Stuttgart · Düsseldorf
- Trading Venues
- Xetra · Tradegate
- Contact
- investors@vidacpharma.com
Investment Overview
- ✦USD 22.8M invested by private investors since 2012
- ✦USD 4.9M invested by CSO and Innovation Authorities
- ✦Listed on three German exchanges under BaFin authorisation
- ✦Winner of the Seal of Excellence from Horizon Europe EIC
- ✦Management buyout by Herzberg and Richter in 2019
- ✦Company funded by shareholder and management investments since 2019
Financial Calendar
Upcoming
Unaudited interim financial statements (six months ended 30 June 2026)
HealthTech Innovation Days
Paris, France
Past Events
19th Annual European Life Sciences CEO Forum — Sachs Associates (attendance cancelled)
Zurich, Switzerland
11th ILANIT / FISEB Conference
Eilat, Israel
First patient dosed in Phase 2B trial
Virtual investor conference (850 attendees)
Phase 2B trial initiation at CentroDerm (Germany)
Germany
Prospectus publication
Düsseldorf Stock Exchange application
18th Annual European Life Sciences CEO Forum — Sachs Associates
Zurich, Switzerland
Eilat Symposium on Pediatric Cancer — Compassionate Use Presentation
Eilat, Israel
Annual Report 2024 publication
17th Annual European Life Sciences CEO Forum — Sachs Associates
Zurich, Switzerland
Annual Report 2023 publication
HealthTech Innovation Days (HTID)
Israel
Financial Reports & Documents
Securities Prospectus
Annual Reports
Interim Reports
Corporate Governance
Analyst Coverage
- 📄
Sphene Capital — Initiation Report (Jun 2024)
2024-06-01
- 📄
Sphene Capital — Update Report (Jul 2024)
2024-07-01
- 📄
Sphene Capital — Update Report (Nov 2024)
2024-11-20
- 📄
Sphene Capital — IP Valuation Analysis (Feb 2025)
2025-02-01
- 📄
Sphene Capital — Update Report (Jun 2025)
2025-06-01
- 📄
Sphene Capital — Update Report (Aug 2025)
2025-08-01
- 📄
Sphene Capital — Update Report (Nov 2025)
2025-11-01
Analyst Coverage
Coverage provided by Sphene Capital GmbH
Sphene Capital provides independent equity research coverage of Vidac Pharma. Research reports are available in the Documents section above under "Analyst Coverage".
Securities Disclaimer
Important Legal Notice — Geographic Restrictions
The documents and information on this page are NOT INTENDED FOR PERSONS RESIDING IN THE UNITED STATES OF AMERICA, nor for persons in Australia, Canada, Israel, Japan, New Zealand, or their respective territories and possessions.
These documents do not constitute an offer to sell securities or a solicitation of an offer to purchase securities in any jurisdiction where such offer or sale is not permitted. The public offer is limited to the Federal Republic of Germany only, conducted exclusively under German law.
Shares of Vidac Pharma Holdings PLC have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, US persons except pursuant to applicable exemptions.
The securities prospectus has been approved by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin).
This website and its content do not constitute investment advice. Past performance is not indicative of future results. Please read our full Disclaimer and Privacy Policy.